Abstract

BackgroundThe serine-threonine kinase AKT1 plays essential roles during normal mammary gland development as well as the initiation and progression of breast cancer. AKT1 is generally considered a ubiquitously expressed gene, and its persistent activation is transcriptionally controlled by regulatory elements characteristic of housekeeping gene promoters. We recently identified a novel Akt1 transcript in mice (Akt1m), which is induced by growth factors and their signal transducers of transcription from a previously unknown promoter. The purpose of this study was to examine whether normal and neoplastic human breast epithelial cells express an orthologous AKT1m transcript and whether its expression is deregulated in cancer cells.MethodsInitial sequence analyses were performed using the UCSC Genome Browser and GenBank to assess the potential occurrence of an AKT1m transcript variant in human cells and to identify conserved promoter sequences that are orthologous to the murine Akt1m. Quantitative RT-PCR was used to determine the transcriptional activation of AKT1m in mouse mammary tumors as well as 41 normal and neoplastic human breast epithelial cell lines and selected primary breast cancers.ResultsWe identified four new AKT1 transcript variants in human breast cancer cells that are orthologous to the murine Akt1m and that encode the full-length kinase. These transcripts originate from an alternative promoter that is conserved between humans and mice. Akt1m is upregulated in the majority of luminal-type and basal-type mammary cancers in four different genetically engineered mouse models. Similarly, a subset of human breast cancer cell lines and primary breast cancers exhibited a higher expression of orthologous AKT1m transcripts.ConclusionsThe existence of an alternative promoter that drives the expression of the unique AKT1m transcript may provide a mechanism by which the levels of AKT1 can be temporally and spatially regulated at particular physiological states, such as cancer, where a heightened activity of this kinase is required.

Highlights

  • The serine-threonine kinase AKT1 plays essential roles during normal mammary gland development as well as the initiation and progression of breast cancer

  • We examined the expression of Akt1 transcript in mice (Akt1m) in primary cancers from Breast cancer 1 susceptibility gene (BRCA1) conditional knockout mice (Brca1−/−), PtenG129E mutant females as well as transgenic mice that overexpress ERBB2 (MMTV-neu) and prolactin (NRL-PRL)

  • These models represent the major breast cancer subtypes found in humans, including triple-negative, basal-type lesions lacking BRCA1, HER2/ERBB2-positive tumors, as well as Estrogen receptor alpha (ERα)-negative and ERα-positive, luminal-type cancers that originate in mice expressing mutant Phosphatase and tensin homolog (PTEN) and prolactin in the mammary gland

Read more

Summary

Introduction

The serine-threonine kinase AKT1 plays essential roles during normal mammary gland development as well as the initiation and progression of breast cancer. Expression of Akt1m mRNA from this promoter is controlled by prolactin and JAK2/ STAT5 signaling and is upregulated more than 500-fold during lactation compared to the virgin mammary gland, contributing to more than a 7-fold increase in total Akt mRNA The identification of this growth factor-induced promoter in mice provides a mechanism by which the levels of AKT1 can be temporally and spatially regulated at particular physiological states where heightened AKT1 activity is required (e.g., during lactation when metabolic needs are high)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call